Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 24

    1.

    The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients.

    Hansen L, Ekstrøm CT, Tabanera Y Palacios R, Anant M, Wassermann K, Reinhardt RR.

    J Clin Endocrinol Metab. 2006 Sep;91(9):3446-50. Epub 2006 Jul 5.PMID: 16822823 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm.

    Saad MF, Greco S, Osei K, Lewin AJ, Edwards C, Nunez M, Reinhardt RR; Ragaglitazar Dose-Ranging Study Group.

    Diabetes Care. 2004 Jun;27(6):1324-9.PMID: 15161783 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Young and elderly type 2 diabetic patients inhaling insulin with the AERx insulin diabetes management system: a pharmacokinetic and pharmacodynamic comparison.

    Henry RR, Mudaliar S, Chu N, Kim D, Armstrong D, Davis TT, An B, Reinhardt RR.

    J Clin Pharmacol. 2003 Nov;43(11):1228-34.PMID: 14551177 [PubMed - indexed for MEDLINE]Related articles

    4.

    Effects of different durations of breath holding after inhalation of insulin using the AERx insulin diabetes management system.

    An B, Reinhardt RR.

    Clin Ther. 2003 Aug;25(8):2233-44.PMID: 14512131 [PubMed - indexed for MEDLINE]Related articles

    5.

    Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study.

    Raskin P, Bode BW, Marks JB, Hirsch IB, Weinstein RL, McGill JB, Peterson GE, Mudaliar SR, Reinhardt RR.

    Diabetes Care. 2003 Sep;26(9):2598-603.PMID: 12941725 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects.

    Henry RR, Mudaliar SR, Howland WC 3rd, Chu N, Kim D, An B, Reinhardt RR.

    Diabetes Care. 2003 Mar;26(3):764-9.PMID: 12610035 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.

    Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer ML, Riviere A, Thant M, Brestan E, Bui B, Eldridge K, De Smet M, Michiels N, Reinhardt RR, Carides AD, Evans JK, Gertz BJ.

    Cancer. 2002 Jun 1;94(11):3032-41.PMID: 12115394 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes.

    Bode B, Weinstein R, Bell D, McGill J, Nadeau D, Raskin P, Davidson J, Henry R, Huang WC, Reinhardt RR.

    Diabetes Care. 2002 Mar;25(3):439-44.PMID: 11874927 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.

    Cocquyt V, Van Belle S, Reinhardt RR, Decramer ML, O'Brien M, Schellens JH, Borms M, Verbeke L, Van Aelst F, De Smet M, Carides AD, Eldridge K, Gertz BJ.

    Eur J Cancer. 2001 May;37(7):835-42.PMID: 11313170 [PubMed - indexed for MEDLINE]Related articles

    10.

    Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.

    Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, Martinez-Cedillo J, Erazo A, Wittreich J, Eriksson LO, Carides AD, Gertz BJ.

    J Clin Oncol. 2001 Mar 15;19(6):1759-67.PMID: 11251007 [PubMed - indexed for MEDLINE]Related articles

    11.

    Insulin-like growth factor 1 regulates developing brain glucose metabolism.

    Cheng CM, Reinhardt RR, Lee WH, Joncas G, Patel SC, Bondy CA.

    Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10236-41.PMID: 10954733 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.

    Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Carides AD, Gertz BJ.

    N Engl J Med. 1999 Jan 21;340(3):190-5.PMID: 9917226 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Biochemical and morphometric analyses show that myelination in the insulin-like growth factor 1 null brain is proportionate to its neuronal composition.

    Cheng CM, Joncas G, Reinhardt RR, Farrer R, Quarles R, Janssen J, McDonald MP, Crawley JN, Powell-Braxton L, Bondy CA.

    J Neurosci. 1998 Aug 1;18(15):5673-81.PMID: 9671658 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases.

    Reinhardt RR, Chin E, Zhou J, Taira M, Murata T, Manganiello VC, Bondy CA.

    J Clin Invest. 1995 Apr;95(4):1528-38. Erratum in: J Clin Invest 1997 Feb 1;99(3):551. PMID: 7706458 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Insulin-like growth factors cross the blood-brain barrier.

    Reinhardt RR, Bondy CA.

    Endocrinology. 1994 Nov;135(5):1753-61.PMID: 7525251 [PubMed - indexed for MEDLINE]Related articles

    17.

    Selective coexpression of insulin receptor-related receptor (IRR) and TRK in NGF-sensitive neurons.

    Reinhardt RR, Chin E, Zhang B, Roth RA, Bondy CA.

    J Neurosci. 1994 Aug;14(8):4674-83.PMID: 8046442 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Cellular distribution of insulin-degrading enzyme gene expression. Comparison with insulin and insulin-like growth factor receptors.

    Bondy CA, Zhou J, Chin E, Reinhardt RR, Ding L, Roth RA.

    J Clin Invest. 1994 Mar;93(3):966-73.PMID: 8132782 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Insulin receptor-related receptor messenger ribonucleic acid is focally expressed in sympathetic and sensory neurons and renal distal tubule cells.

    Reinhardt RR, Chin E, Zhang B, Roth RA, Bondy CA.

    Endocrinology. 1993 Jul;133(1):3-10.PMID: 8319578 [PubMed - indexed for MEDLINE]Related articles

    20.

    Adenosine inhibits choline kinase activity and decreases the phosphorylation of choline in striatal synaptosomes.

    Wecker L, Reinhardt RR.

    J Neurochem. 1988 Jun;50(6):1945-51.PMID: 2836562 [PubMed - indexed for MEDLINE]Related articles

    21.

    Cardiac cholinergic muscarinic receptors: changes in multiple affinity forms with down-regulation.

    Roskoski R Jr, Reinhardt RR, Enseleit W, Johnson WD, Cook PF.

    J Pharmacol Exp Ther. 1985 Mar;232(3):754-9.PMID: 3882936 [PubMed - indexed for MEDLINE]Related articles

    22.

    Kinetic mechanism of choline kinase from rat striata.

    Reinhardt RR, Wecker L, Cook PF.

    J Biol Chem. 1984 Jun 25;259(12):7446-52.PMID: 6330058 [PubMed - indexed for MEDLINE]Related articlesFree article

    23.

    Evidence for membrane-associated choline kinase activity in rat striatum.

    Reinhardt RR, Wecker L.

    J Neurochem. 1983 Sep;41(3):623-9.PMID: 6308165 [PubMed - indexed for MEDLINE]Related articles

    24.

    Methacholine-induced decrease in the cholinergic muscarinic receptor content in the perfused working rat heart.

    Reinhardt RR, Roskoski R Jr.

    J Pharmacol Exp Ther. 1983 Jul;226(1):135-9.PMID: 6345753 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data

    Search details

    » See more...

    Recent activity

    Your browsing activity is temporarily unavailable.

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    » See more...